Doximity, Inc.(DOCS)NASDAQ
Stock Overview & Analysis
Doximity, Inc. (DOCS) quick overview 2026-02-20
- The stock is currently trading at $25.55, experiencing a short-term pullback within a declining trend—trading below its 50-day average while below the 200-day.
- Analysts appear optimistic, with a 1-year price target of $40.19 (57.3% upside).
- Volatility is elevated (58.34% annualized), implying wide price swings.
- The fundamental story is nuanced: solid revenue growth (9.80% YoY) alongside significant competitive pressures.
Here's What You Need to Know Right Now
Concise, actionable context
Doximity, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $3.98B
P/E Ratio
Forward P/E: 15.48
Revenue Growth
Year over Year
Analyst Target
+57.3% upside potential
Key Investor Questions
Clarity over jargon
- Technicals say: Oversold (RSI 20.56)
- Fundamentals say: Looking solid (debt and growth supportive)
- Future growth will depend on performance in core Health Information Services operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
- $10.69M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Health Information Services.
Trading Range
Over the past year, the stock traded between $23.66 and $79.97—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility
With 58.34% annualized volatility and β=1.39, the stock exhibits high sensitivity to market moves—suitable for investors comfortable with active risk management.
Ownership Snapshot
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment
Latest News
Recent headlines and coverage
Down Over 30% This Year: Analysts Double Down on These 3 Beaten-Down Stocks
What should you do with a stock that’s been falling? Some would say, sell it now and cut your losses – but others say, look for opportunities. There are a myriad of reasons why a stock can fall, but Wall Street’s analysts will tell you that you need to read those reasons with care. In some cases, the decline reflects genuine deterioration – weakening fundamentals, shrinking demand, or a business model that no longer fits the market. Those are red flags investors need to recognize. In other insta
Teladoc Q4 Earnings: Can Integrated Care Strength Save Profits?
TDOC heads into Q4 earnings with an improving loss outlook and rising Integrated Care EBITDA, but BetterHelp declines may weigh on revenues.
2 of Wall Street’s Favorite Stocks Worth Your Attention and 1 We Turn Down
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Canaccord Calls Doximity, Inc. (DOCS)’s Post-Earnings Selloff an Overreaction And Sees Long-Term Upside
Doximity, Inc. (NYSE:DOCS) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts. The stock given seventh position on our list of best healthcare stocks is Doximity, Inc. (NYSE:DOCS). TheFly reported on February 9 that Canaccord Genuity upgraded DOCS from Hold to Buy and lowered the price target to $34 from $48. The […]
Doximity (DOCS) Is Down 9.8% After Big Buybacks and Mixed Q3 Signals Has The Bull Case Changed?
Earlier this month, Doximity reported third-quarter fiscal 2026 results showing revenue of US$185.05 million and net income of US$61.56 million, while also issuing fourth-quarter and full-year revenue guidance and completing a US$417.04 million buyback alongside authorizing a new US$500 million repurchase program. The quarter highlighted a tension between solid sales growth and pressure on earnings amid delayed pharmaceutical marketing budgets and higher AI infrastructure spending, even as...
PacBio Q4 Earnings and Revenues Beat Estimates, Gross Margin Up
PACB beats Q4 estimates as revenue jumps 14%, gross margin hits 41% and 2026 revenues are projected in the range of $165-$180M after strategic moves.
Should You Buy, Hold or Sell Tempus AI Stock Pre-Q4 Earnings Release?
In preliminary, unaudited financial results, TEM posts 83% revenue growth and record data sales in 2025, but valuation and ongoing GAAP losses cloud the outlook before Q4 earnings.
AVTR Stock Plunges Despite Q4 Earnings Beat Estimates, Margins Decline
Avantor stock sinks 13% as Q4 earnings beat estimates, but revenues slip, margins contract and 2026 outlook signals more pressure ahead.
QuidelOrtho Q4 Earnings and Revenues Beat Estimates, Margins Down
QDEL beats Q4 estimates as Labs and global growth lift sales, but shrinking margins and respiratory weakness weigh on profits.
Doximity's (NYSE:DOCS) Solid Earnings Have Been Accounted For Conservatively
The stock was sluggish on the back of Doximity, Inc.'s ( NYSE:DOCS ) recent earnings report. We have done some...
Frequently Asked Questions
Common investor questions about Doximity, Inc.
Doximity, Inc. (DOCS) is currently trading at $25.55. The RSI (14-day) is at 20.6, indicating oversold territory (potentially undervalued). Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $40.19 implies 57.3% upside from current levels. Volatility is high at 58.3% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Doximity, Inc. (DOCS): The trailing P/E ratio is 21.14, which is in line with broader market averages. The forward P/E is 15.48, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.69, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 4.75. Price-to-Sales is 7.43. Valuation should be compared to Health Information Services industry peers for context, as different sectors trade at different multiples.
Based on 21 analysts covering DOCS, the consensus price target is $40.19. This represents a 57.3% upside from the current price of $25.55. The range spans from a low target of $25.00 to a high target of $56.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Doximity, Inc. (DOCS) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Doximity, Inc. (DOCS) investors include: 1. High volatility (58.3% annualized)—the stock can experience significant daily price swings. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Health Information Services sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Doximity, Inc.'s (DOCS) current debt and financial health profile: Total debt stands at $10.69M. The debt-to-equity ratio is 1.09, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 6.63, indicating strong short-term liquidity. The quick ratio is 6.00. The company holds $735.13M in cash and equivalents. Free cash flow is positive at $213.63M, providing a cushion for debt servicing and shareholder returns.